VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%

Viking Therapeutics (VKTX) reported a fourth-quarter 2024 loss per share of 32 cents, wider than the Zacks Consensus Estimate of a loss of 27 cents. The company had incurred a loss of 25 cents per share in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Currently, Viking Therapeutics does not have any approved products in its portfolio. Hence, it is yet to generate revenues.More on VKTX’s Q4 EarningsResearch and development expenses surged 51% year over year to $31 m ...